Syndax Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Syndax Pharmaceuticals의 수입은 연평균 -37.2%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19.3%의 비율로 증가했습니다. 매출은 연평균 6.2%의 비율로 증가해 왔습니다.

주요 정보

-37.2%

수익 성장률

-15.0%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	6.2%
자기자본 수익률	-81.1%
순이익	-1,856.6%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

수익 및 비용 분석

Syndax Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:SNDX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	16	-297	106	167
30 Jun 24	4	-264	92	165
31 Mar 24	0	-241	78	185
31 Dec 23	0	-209	67	163
30 Sep 23	0	-176	54	42
30 Jun 23	0	-160	45	65
31 Mar 23	0	-153	38	123
31 Dec 22	0	-149	33	118
30 Sep 22	127	-14	30	111
30 Jun 22	139	1	29	109
31 Mar 22	139	15	26	96
31 Dec 21	140	25	25	88
30 Sep 21	14	-92	23	80
30 Jun 21	2	-91	22	69
31 Mar 21	2	-86	22	63
31 Dec 20	2	-77	23	50
30 Sep 20	2	-71	23	44
30 Jun 20	2	-63	21	40
31 Mar 20	2	-61	18	41
31 Dec 19	2	-56	16	43
30 Sep 19	2	-61	15	49
30 Jun 19	2	-65	15	53
31 Mar 19	2	-69	16	56
31 Dec 18	2	-74	17	60
30 Sep 18	2	-74	17	61
30 Jun 18	2	-72	17	59
31 Mar 18	2	-67	17	54
31 Dec 17	2	-61	16	48
30 Sep 17	1	-53	15	40
30 Jun 17	1	-52	14	40
31 Mar 17	1	-47	13	36
31 Dec 16	1	-47	13	32
30 Sep 16	1	-45	11	26
30 Jun 16	1	-87	11	16
31 Mar 16	1	-105	12	13
31 Dec 15	1	-104	12	10
30 Sep 15	0	-100	11	8
30 Jun 15	0	-53	14	8
31 Mar 15	0	-33	12	10
31 Dec 14	0	-26	11	10
30 Sep 14	0	-31	11	10
30 Jun 14	0	-72	7	8
31 Mar 14	0	-67	6	5

양질의 수익: SNDX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SNDX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SNDX 은(는) 수익성이 없으며 지난 5년 동안 연간 37.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SNDX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SNDX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SNDX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -81.07% )을 갖습니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 14:57
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Syndax Pharmaceuticals, Inc. 23 애널리스트 중 13 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Peter Lawson	Barclays
Jason Zemansky	BofA Global Research
Madhu Kumar	B. Riley Securities, Inc.

Syndax Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? (Revumenib) from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial

Syndax Pharmaceuticals Presents Positive Revuforj Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Consensus revenue estimates increase by 197%

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 11%, EPS upgraded

Director exercised options and sold US$715k worth of stock

Director exercised options and sold US$794k worth of stock

Syndax Pharmaceuticals, Inc. Announces Executive Changes

President exercised options and sold US$695k worth of stock

President exercised options and sold US$853k worth of stock

Consensus EPS estimates fall by 21%

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Price target increased by 7.6% to US$34.44

Independent Director exercised options and sold US$616k worth of stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Consensus revenue estimates increase by 64%

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CEO & Director exercised options and sold US$549k worth of stock

President exercised options and sold US$4.4m worth of stock

Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock

Consensus forecasts updated

Independent Director exercised options and sold US$331k worth of stock

First half 2022 earnings released

Syndax Pharmaceuticals Q2 2022 Earnings Preview